Register for updates

 
 

Medicine & Health
RSS Feed
New Platform Based on Biology and Nanotechnology Carries mRNA Directly to Target Cells
Monday, October 29, 2018 9:00:00 AM

Combined platform provides safe, effective passage for therapies treating cancer and other diseases, TAU researchers say

Delivering an effective therapeutic payload to specific target cells with few adverse effects is considered by many to be the holy grail of medical research. A new Tel Aviv University study explores a biological approach to directing nanocarriers loaded with protein "game changers" to specific cells. The groundbreaking method may prove useful in treating myriad malignancies, inflammatory diseases and rare genetic disorders.

Prof. Dan Peer, director of the Laboratory of Precision Nanomedicine at the School of Molecular Cell Biology at TAU's Faculty of Life Sciences, led the research for the new study, which was conducted by TAU graduate student Nuphar Veiga and lab colleagues Meir Goldsmith, Yasmin Granot, Daniel Rosenblum, Niels Dammes, Ranit Kedmi and Srinivas Ramishetti. The research was published in Nature Communications.

Over the past few years, lipid carriers encapsulating messenger RNAs (mRNAs) have been shown to be extremely useful in altering the protein expressions for a host of diseases. But directing this information to specific cells has remained a major challenge.

"In our new research, we utilized mRNA-loaded carriers — nanovehicles carrying a set of genetic instructions via a biological platform called ASSET — to target the genetic instructions of an anti-inflammatory protein in immune cells," says Prof. Peer. "We were able to demonstrate that selective anti-inflammatory protein in the target cells resulted in reduced symptoms and disease severity in colitis.

"This research is revolutionary. It paves the way for the introduction of an mRNA that could encode any protein lacking in cells, with direct applications for genetic, inflammatory and autoimmune diseases — not to mention cancer, in which certain genes overexpress themselves."

ASSET (Anchored Secondary scFv Enabling Targeting) uses a biological approach to direct nanocarriers into specific cells to promote gene manipulation.

"This study opens new avenues in cell-specific delivery of mRNA molecules and ultimately might introduce the specific anti-inflammatory (interleukin 10) mRNA as a novel therapeutic modality for inflammatory bowel diseases," says Ms. Veiga.

"Targeted mRNA-based protein production has both therapeutic and research applications," she concludes. "Going forward, we intend to utilize targeted mRNA delivery for the investigation of novel therapeutics treating inflammation disorders, cancer and rare genetic diseases."

Photo captions:

Top right: Schematic illustration of the mechanism by which the lab's targeted nanoparticles modulate gene expression in the target cell. Credit: Nuphar Veiga.

Middle left: Peer lab team. Left to right: Yasmin Granot, Dr. Meir Goldsmith, Niels Dammes, Nuphar Veiga, Prof. Dan Peer, Dr. Srinivas Ramishetti and Daniel Rosenblum. Credit: Anna Gutkin.




Latest News

Breast Cancer Recruits Bone Marrow Cells to Increase Cancer Cell Proliferation

Cancer-associated fibroblasts are derived from bone marrow cells called mesenchymal stromal cells, TAU researchers say.

Epigenetic Map May Pave Way for New Therapeutic Solutions to Hearing Loss

Understanding the expression of and controlling the genes involved in hearing are milestone discoveries, TAU researchers say.

Gas Clouds Whirling Around Black Hole Form Heart of Extremely Distant Luminous Astronomical Object

Discovery is the first detailed observation of the environs of a massive black hole outside the Milky Way.

The Tactics Behind "Taking to the Streets"

A new book by TAU researcher explores importance of public space in the design of social protests.

Training Program for Adults with Intellectual Disabilities Opens at TAU's School of Dental Medicine

Pilot program launched by TAU and AKIM helps students find jobs and changes attitudes about people with special needs.

TAU and its American Friends to Honor Susan and Henry Samueli at International Gala in Los Angeles

Philanthropists and Stanley Cup Winners to be recognized; Noa Tishby to serve as event emcee.

Astronomers Discover Giant Relic of Disrupted "Tadpole" Galaxy

Discovery illuminates how and why galaxies disappear, say TAU researchers.

Drug Candidate May Recover Vocal Abilities Lost to ADNP Syndrome

Protein snippet normalizes disrupted neural connectivity caused by genetic disorder, TAU researchers say.

TAU and Northwestern University Launch Joint Nanoscience Program

Collaboration to include student exchange program, post-doctoral scholarships and research grants.

Scientists Use Patients' Own Cells and Materials to Engineer Fully Personalized Tissue Implants of Any Kind

Risk of an immune response to an organ implant virtually disappears, TAU researchers say.

contentSecondary
c

© 2018 American Friends of Tel Aviv University
39 Broadway, Suite 1510 | New York, NY 10006 | 212.742.9070 | info@aftau.org
Privacy policy | Tel Aviv University